Shanghai Medicilon, Inc. Class A
SSSE:68820277.90
CNY
-3.89
(-4.76%)
ISIN
CNE100003NQ8
Return %
Stock
S&P 500
1Y
24.02
14.20
3Y
8.91
81.12
5Y
-78.13
68.34
Capital Structure
CNY
•
in mil. unless spec.Working Capital
CNY
•
in mil. unless spec.Growth Rates
CNY
•
in mil. unless spec.Quarterly Revenue
CNY
•
in mil. unless spec.Quarterly Earnings Per Share
CNY
•
in mil. unless spec.Quarterly Dividends Per Share
CNY
•
in mil. unless spec.Company Description
- CEO
- Chun Lin Chen
- Full Time Employees
- 2,504
- Sector
- Commercial services
- Industry
- Miscellaneous commercial services
- Address
- Shanghai China
- IPO Date
- Nov 5, 2019
- Website
- medicilon.com.cn
- Similar Companies
- Business
- Shanghai Medicilon, Inc. is a contract research organization that provides comprehensive preclinical drug discovery, development, and evaluation services to biotechnology and pharmaceutical companies, universities, and research institutions worldwide. Founded in 2004 and headquartered in Shanghai, China, the company operates specialized laboratory and research facilities across the Zhangjiang High-Tech Park and Chuansha Economic Park in Shanghai, alongside commercial operations serving clients across North America, Europe, and the Asia-Pacific region. Medicilon delivers integrated, one-stop preclinical research solutions spanning the entire early-stage pharmaceutical research and development spectrum. The company’s core service offerings comprise: drug discovery services, including target validation, computer-aided drug design, high-throughput screening, hit-to-lead identification, lead optimization, medicinal chemistry, structural biology, and synthetic chemistry; pharmaceutical chemistry and chemistry, manufacturing, and controls services, including active pharmaceutical ingredient route scouting, synthetic process development, formulation development, solid-state characterization, analytical method development and validation, stability testing, and pilot-scale manufacturing; and preclinical pharmacology, pharmacokinetics, and safety assessment services, encompassing in vitro and in vivo disease modeling, absorption, distribution, metabolism, and excretion profiling, Good Laboratory Practice-compliant toxicology testing, safety pharmacology, immunogenicity assessment, and comprehensive Investigational New Drug-enabling study packages. The company supports a broad spectrum of therapeutic modalities through dedicated technical platforms for small molecules, biologics, antibody-drug conjugates, proteolysis targeting chimeras, peptide therapeutics, small interfering RNA, and cell and gene therapies. In recent developments, Medicilon has expanded its technological capabilities and broadened its commercial partnerships to accelerate preclinical research pipelines. The company entered into a strategic partnership with Oncotelic Therapeutics to provide rapid Investigational New Drug development platform support across multiple oncology projects, alongside collaborative alliances established with Binhui Biopharmaceutical and Innoforce Pharmaceuticals. Additionally, Medicilon launched its proprietary AI-integrated drug discovery platform, incorporating organoid-based efficacy testing and advanced disease modeling to enhance preclinical screening accuracy and streamline cross-border regulatory submissions for global pharmaceutical clients.